Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Focus Minnesota.
Press releases published on October 21, 2025
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Series on Thursday, …
Sotera Health Announces Third-Quarter 2025 Earnings Release Date
CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will …
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that …
Jushi Holdings Inc. to Report Third Quarter 2025 Financial Results on November 4, 2025
BOCA RATON, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the third …
Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa
Teva und Prestige geben eine Lizenz- und Liefervereinbarung für die Vermarktung des von Prestige hergestellten Arzneimittels Tuznue® bekannt, einem Biosimilar zu Herceptin® (trastuzumab) Die Europäische Kommission (EK) erteilte Tuznue® im September 2024 …
Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe
Teva et Prestige annoncent un accord de licence et d’approvisionnement pour la commercialisation de Tuznue®, un biosimilaire d’Herceptin® (trastuzumab) produit par Prestige Tuznue® a reçu l’autorisation de mise sur le marché de la Commission européenne (CE …
Aveanna Healthcare Holdings Announces Preliminary Third Quarter Financial Results
ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced certain preliminary …
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it …
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
TORONTO and HAIFA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing exosome-based regenerative therapies, announced that Dr. Ina …
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients …
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will …
National Down Syndrome Society Launches CARE Down Syndrome
Washington D.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- The National Down Syndrome Society (NDSS) is proud to announce the launch of its initiative, CARE Down Syndrome, a comprehensive, free online clinical education and resource hub designed to equip …
Fairhaven Health Highlights Science-Driven Solutions for Women During Menopause Awareness Month
MIDDLETOWN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- October marks Menopause Awareness Month, a time to focus on the physical and emotional changes that affect more than 1 million American women each year. Fairhaven Health, a leader in women’s reproductive …
Cicero Institute Applauds Gov. Abbott’s Action on Homelessness in Austin
Austin, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The Cicero Institute applauds Gov. Greg Abbott's announcement today that he is "dedicated to making Austin safer and cleaner by relocating homeless individuals and removing encampments in and around the capital …
Diabetes Canada launches campaign calling for school-based standards of care for kids living with diabetes
Toronto, Oct. 21, 2025 (GLOBE NEWSWIRE) -- At a media conference at the Ontario Legislature today, Diabetes Canada announced the launch of a nationwide advocacy campaign aimed at ensuring consistent, safe, and equitable support for all students living with …
Türkiye Sets the Stage in Germany ALZ Group to Host its 14th Expo
Photo: ALZ Group via FL Comms. FRANKFURT, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The 3rd Frankfurt International Health Tourism Expo, organized by ALZ Group, is set to open its doors on October 24–25, 2025, at the Messe Frankfurt Congress Center. …
What Americans Fear Most in 2025: Chapman University’s Annual Fear Study Reveals What’s Driving Americans’ Anxieties
Media Kit: Full Report, Methodology, Graphs, B-roll and Soundbites ORANGE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Chapman University today released the results of its 11th annual Chapman University Survey of American Fears, a nationally representative …
Quercis Pharma and The Galien Foundation to Spotlight Sickle Cell Disease at the 2025 Patient Summit
NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Quercis Pharma is proud to sponsor Panel 6 — “The Forgotten Patients: A Focus on Sickle Cell Disease” at The Galien Foundation’s 2025 Patient Summit, taking place on Thursday, October 30, 2025, at the Alexandria …